Astellas Pharma Australia

16 PBAC submissions on file, active 2014–2025. 81% have been recommended.

Drug portfolio

Sorted by PBS spend captured. PBS expenditure is credited to the sponsor with the most recent Recommended decision per drug, so biosimilars and originator brands aren't double-counted.

• Enzalutamide
  Oncology · Recommended with restriction · 2024$158M
• Enfortumab vedotin
  Oncology · Recommended with restriction · 2024—
• Fezolinetant
  Women's health · Not recommended · 2025—
• Gilteritinib
  Haematology · Recommended with restriction · 2022—
• Tacrolimus
  Dermatology · Recommended with restriction · 2025other sponsor
• Zolbetuximab
  Oncology · Recommended with restriction · 2025—

Therapy area mix

Activity by year

2014 (1) · 2015 (1) · 2017 (2) · 2019 (1) · 2021 (1) · 2022 (4) · 2023 (1) · 2024 (2) · 2025 (3)

Rejection patterns

Across 2 Not recommended decisions on file.

• 1×Treatment should not be restricted to asymptomatic patients
• 1×definition of 'asymptomatic' based on opioid use is vague and could distort clinical practice
• 1×economic model driven by unjustified assumptions about progression-free survival and did not appropriately reflect the value of early enzalutamide
• 1×exclusion of symptomatic patients creates inequity
• 1×Clinical place not well-defined